A surge in revenue during the first half of 2021 puts the Next Science share price in the green today…
The post Next Science (ASX:NXS) share price jumps on record revenue growth appeared first on The Motley Fool Australia. –
The Next Science Ltd (ASX: NXS) share price is charging higher today.
At the time of writing, the medical technology company’s shares are up 4.05% to $1.54.
Why is the Next Science share price rallying today?
Investors are looking at the Next Science share price more optimistically following the release of its second quarter update.
According to the release, the company pulled in US$3.9 million in revenue for the first half. This reflected an increase of 271% on the prior corresponding period.
Pleasingly for shareholders, this was a record rate of growth from Next Science.
Additionally, its XPerience No Rinse Antimicrobial Solution was cleared by the United States Food and Drug Administration.
The solution helps prevent surgical site biofilm based infections.
The approval process for use in US hospitals is now underway.
Furthermore, Next Science’s antimicrobial wound gel, BlastX returned to the company and sales commenced.
Next Science regained the global distribution rights to BlastX from 3M (NYSE: MMM) in April 2021.
The patented medical product has also received approval from Australia’s Therapeutic Goods Administration (TGA).
After burning through US$1.9 million in cash during the first half, the company maintains US$13.2 million cash on hand.
Managing Director commentary
Managing Director, Judith Mitchell spoke about the record result for the company:
The strategies we are executing to commercialise our proprietary Xbio technology platform are delivering record results. The 271% revenue growth we have reported for 1H was driven by sales from our existing products.
Following the approval of our market leading “no rinse antimicrobial solution”, XPerience, by the FDA on 23 April, we are building an excellent platform for future growth. Our focus has been to secure VAC approvals across US hospitals to facilitate commercial sales in the US. As at mid-July, we had made 123 VAC submissions covering 211 hospitals and we had received 20 approvals.
Next Science share price snapshot
Thanks to today’s gains, the Next Science share price is 18.46% higher over the past year.
However, investors who bought at the 52-week high of $2.06 in June are still down 25.24%.
Should you invest $1,000 in Next Science right now?
Before you consider Next Science, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Next Science wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of May 24th 2021
The Prospa (ASX:PGL) share price is up 12% today. Here’s why
Wisr (ASX:WZR) share price remains flat despite positive update
Why the Peak Resources (ASX:PEK) share price is soaring 37% today
Why the Pilbara Minerals (ASX:PLS) share price is up 9% this Thursday
Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended Next Science Limited. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.